精品国产_亚洲人成在线高清,国产精品成人久久久久,国语自产偷拍精品视频偷拍

首頁(yè) 500強(qiáng) 活動(dòng) 榜單 商業(yè) 科技 領(lǐng)導(dǎo)力 專題 品牌中心
雜志訂閱

獲得“超級(jí)免疫”,意味著什么?

SOPHIE MELLOR
2022-01-04

已接種疫苗者若出現(xiàn)突破性感染,可形成“超級(jí)免疫”。

文本設(shè)置
小號(hào)
默認(rèn)
大號(hào)
Plus(0條)

如果你近期曾經(jīng)感染新冠并已恢復(fù),現(xiàn)在是否可以隨心所欲想干什么就干什么?最新的研究表明,曾經(jīng)感染新冠確實(shí)能大大降低你再次感染的幾率。

雖然一些早期研究認(rèn)為,如果曾經(jīng)感染奧密克戎,極可能會(huì)產(chǎn)生相應(yīng)抗體,但要知道,大多數(shù)人并不能確定感染的是哪一種新冠毒株。據(jù)美國(guó)疾病控制與預(yù)防中心估計(jì),在美國(guó),奧密克戎變種占目前全部新冠感染病例的59%,德爾塔變種占剩余的41%。眼下,關(guān)于每種毒株的再感染率幾乎沒(méi)有任何數(shù)據(jù)。不過(guò),南非一篇預(yù)印本研究論文發(fā)現(xiàn),奧密克戎感染或許會(huì)增加對(duì)德爾塔變種的免疫力。

這項(xiàng)研究由非洲健康研究所(Africa Health Research Institute)開展,正是該所研究人員首次發(fā)現(xiàn),兩劑輝瑞疫苗對(duì)奧密克戎的免疫應(yīng)答較弱。他們?cè)诒敬窝芯恐凶粉櫫?3個(gè)人,其中11人感染了奧密克戎毒株。他們發(fā)現(xiàn),在參與者加入研究?jī)芍芎螅腥緤W密克戎的人對(duì)德爾塔的抗體反應(yīng)增加了四倍。同時(shí),他們發(fā)現(xiàn),奧密克戎感染對(duì)再次感染同種毒株的保護(hù)力提高了14倍。

這些發(fā)現(xiàn)意味著,奧密克戎可以取代德爾塔成為新冠病毒的主要毒株。由哈迪賈·可汗領(lǐng)導(dǎo)的科學(xué)家團(tuán)隊(duì)在研究結(jié)果中寫道:“研究結(jié)果與奧密克戎將取代德爾塔變種的結(jié)論一致,因?yàn)閵W密克戎變種可以引發(fā)免疫,中和德爾塔病毒,從而降低再次感染德爾塔病毒的可能性。”

科學(xué)家們指出,如果奧密克戎取代了德爾塔,且如果奧密克戎確實(shí)如早期研究結(jié)果所述不易產(chǎn)生重癥,“新冠肺炎重癥的發(fā)病率將降低,病毒感染對(duì)個(gè)體和社會(huì)的影響將變小。”盡管存在上述預(yù)測(cè),世界衛(wèi)生組織仍警告稱,現(xiàn)在斷言?shī)W米克戎總體上是否更溫和還為時(shí)過(guò)早。

俄勒岡健康與科學(xué)大學(xué)(Oregon Health & Science University)的另外一項(xiàng)研究發(fā)現(xiàn),已接種疫苗者若出現(xiàn)突破性感染,可形成“超級(jí)免疫”。該研究對(duì)比了該大學(xué)52名曾接種過(guò)輝瑞疫苗但出現(xiàn)突破性感染的員工的血液樣本,這些員工感染的毒株包括阿爾法、貝塔、伽馬和德爾塔。

研究發(fā)現(xiàn),突破性感染出現(xiàn)后產(chǎn)生的抗體,比接種完輝瑞疫苗第二針兩周后產(chǎn)生的抗體更多、更有效。“沒(méi)有比這更好的免疫應(yīng)答了,”報(bào)告作者、俄勒岡健康與科學(xué)大學(xué)醫(yī)學(xué)院助理教授菲卡杜·塔費(fèi)瑟說(shuō)。

“我們沒(méi)有專門研究奧密克戎毒株的情況,”塔費(fèi)瑟補(bǔ)充說(shuō),“但根據(jù)研究結(jié)果,我們預(yù)計(jì),奧密克戎毒株產(chǎn)生的突破性感染將在已接種疫苗的人群中產(chǎn)生同樣強(qiáng)烈的免疫反應(yīng)。”

鑒于這波疫情中感染新冠肺炎病毒的人數(shù)眾多,如感染者的免疫力提高,或許意味著疫情可能很快會(huì)緩解。“急速上升的感染人數(shù)正在逐步建立起群體免疫力。這將對(duì)抑制未來(lái)的疫情擴(kuò)散至關(guān)重要,”凱撒家庭基金會(huì)(Kaiser Family Foundation)全球衛(wèi)生政策副主任約書亞·米肖向Vox表示。

然而,奧密克戎已被證明能夠很好地避開以前不同變種的感染。來(lái)自南非的預(yù)印本研究論文發(fā)現(xiàn),南非第四波疫情期間,再次感染奧密克戎的風(fēng)險(xiǎn)遠(yuǎn)遠(yuǎn)高于該國(guó)第二波和第三波疫情期間再次感染的風(fēng)險(xiǎn),上兩波疫情分別以貝塔和德爾塔為主。倫敦帝國(guó)理工學(xué)院的另一項(xiàng)研究發(fā)現(xiàn),再次感染奧密克戎變種的風(fēng)險(xiǎn)是德爾塔變種的5.4倍。(財(cái)富中文網(wǎng))

譯者:Agatha

如果你近期曾經(jīng)感染新冠并已恢復(fù),現(xiàn)在是否可以隨心所欲想干什么就干什么?最新的研究表明,曾經(jīng)感染新冠確實(shí)能大大降低你再次感染的幾率。

雖然一些早期研究認(rèn)為,如果曾經(jīng)感染奧密克戎,極可能會(huì)產(chǎn)生相應(yīng)抗體,但要知道,大多數(shù)人并不能確定感染的是哪一種新冠毒株。據(jù)美國(guó)疾病控制與預(yù)防中心估計(jì),在美國(guó),奧密克戎變種占目前全部新冠感染病例的59%,德爾塔變種占剩余的41%。眼下,關(guān)于每種毒株的再感染率幾乎沒(méi)有任何數(shù)據(jù)。不過(guò),南非一篇預(yù)印本研究論文發(fā)現(xiàn),奧密克戎感染或許會(huì)增加對(duì)德爾塔變種的免疫力。

這項(xiàng)研究由非洲健康研究所(Africa Health Research Institute)開展,正是該所研究人員首次發(fā)現(xiàn),兩劑輝瑞疫苗對(duì)奧密克戎的免疫應(yīng)答較弱。他們?cè)诒敬窝芯恐凶粉櫫?3個(gè)人,其中11人感染了奧密克戎毒株。他們發(fā)現(xiàn),在參與者加入研究?jī)芍芎螅腥緤W密克戎的人對(duì)德爾塔的抗體反應(yīng)增加了四倍。同時(shí),他們發(fā)現(xiàn),奧密克戎感染對(duì)再次感染同種毒株的保護(hù)力提高了14倍。

這些發(fā)現(xiàn)意味著,奧密克戎可以取代德爾塔成為新冠病毒的主要毒株。由哈迪賈·可汗領(lǐng)導(dǎo)的科學(xué)家團(tuán)隊(duì)在研究結(jié)果中寫道:“研究結(jié)果與奧密克戎將取代德爾塔變種的結(jié)論一致,因?yàn)閵W密克戎變種可以引發(fā)免疫,中和德爾塔病毒,從而降低再次感染德爾塔病毒的可能性。”

科學(xué)家們指出,如果奧密克戎取代了德爾塔,且如果奧密克戎確實(shí)如早期研究結(jié)果所述不易產(chǎn)生重癥,“新冠肺炎重癥的發(fā)病率將降低,病毒感染對(duì)個(gè)體和社會(huì)的影響將變小。”盡管存在上述預(yù)測(cè),世界衛(wèi)生組織仍警告稱,現(xiàn)在斷言?shī)W米克戎總體上是否更溫和還為時(shí)過(guò)早。

俄勒岡健康與科學(xué)大學(xué)(Oregon Health & Science University)的另外一項(xiàng)研究發(fā)現(xiàn),已接種疫苗者若出現(xiàn)突破性感染,可形成“超級(jí)免疫”。該研究對(duì)比了該大學(xué)52名曾接種過(guò)輝瑞疫苗但出現(xiàn)突破性感染的員工的血液樣本,這些員工感染的毒株包括阿爾法、貝塔、伽馬和德爾塔。

研究發(fā)現(xiàn),突破性感染出現(xiàn)后產(chǎn)生的抗體,比接種完輝瑞疫苗第二針兩周后產(chǎn)生的抗體更多、更有效。“沒(méi)有比這更好的免疫應(yīng)答了,”報(bào)告作者、俄勒岡健康與科學(xué)大學(xué)醫(yī)學(xué)院助理教授菲卡杜·塔費(fèi)瑟說(shuō)。

“我們沒(méi)有專門研究奧密克戎毒株的情況,”塔費(fèi)瑟補(bǔ)充說(shuō),“但根據(jù)研究結(jié)果,我們預(yù)計(jì),奧密克戎毒株產(chǎn)生的突破性感染將在已接種疫苗的人群中產(chǎn)生同樣強(qiáng)烈的免疫反應(yīng)。”

鑒于這波疫情中感染新冠肺炎病毒的人數(shù)眾多,如感染者的免疫力提高,或許意味著疫情可能很快會(huì)緩解。“急速上升的感染人數(shù)正在逐步建立起群體免疫力。這將對(duì)抑制未來(lái)的疫情擴(kuò)散至關(guān)重要,”凱撒家庭基金會(huì)(Kaiser Family Foundation)全球衛(wèi)生政策副主任約書亞·米肖向Vox表示。

然而,奧密克戎已被證明能夠很好地避開以前不同變種的感染。來(lái)自南非的預(yù)印本研究論文發(fā)現(xiàn),南非第四波疫情期間,再次感染奧密克戎的風(fēng)險(xiǎn)遠(yuǎn)遠(yuǎn)高于該國(guó)第二波和第三波疫情期間再次感染的風(fēng)險(xiǎn),上兩波疫情分別以貝塔和德爾塔為主。倫敦帝國(guó)理工學(xué)院的另一項(xiàng)研究發(fā)現(xiàn),再次感染奧密克戎變種的風(fēng)險(xiǎn)是德爾塔變種的5.4倍。(財(cái)富中文網(wǎng))

譯者:Agatha

If you recently tested positive and have since recovered from COVID-19, do you now have free rein to do whatever you want? According to recent studies, prior infection vastly reduces your odds of reinfection.

While some early research has led to promising findings about post-Omicron immunity, it's important to remember that most people can't be sure which strain of SARS-CoV-2 infected them. In the United States, the Omicron variant now represents 59% of COVID-19 cases, and the Delta variant accounts for the remaining 41%, according to CDC estimates. At this juncture, there is little data on the reinfection rates of each strain. One preprint study in South Africa, however, has found that an Omicron infection may increase immunity to the Delta variant.

The study, conducted by the Africa Health Research Institute—the same researchers who first found that two doses of the Pfizer vaccine elicited a weaker immune response against Omicron—followed 13 people, 11 of whom had been infected with the Omicron variant. They found that the antibody response in people previously infected with Omicron increased protection against Delta fourfold two weeks after participants joined the study. Meanwhile, they found prior Omicron infection increased protection against Omicron reinfection 14-fold.

These findings imply Omicron could displace Delta as the dominant strain of the virus. “These results are consistent with Omicron displacing the Delta variant, since it can elicit immunity which neutralizes Delta making re-infection with Delta less likely,” the team of scientists, led by Khadija Khan, wrote in their findings.

The scientists note that if Omicron displaces Delta, and if Omicron indeed causes less severe symptoms as early findings have indicated, “the incidence of COVID-19 severe disease would be reduced and the infection may shift to become less disruptive to individuals and society.” Despite these forecasts, the World Health Organization has warned that it is too soon to assert whether Omicron is milder overall.

Another study, conducted by Oregon Health & Science University, found that a breakthrough infection in a vaccinated person leads to “super immunity." The study compared blood samples from 52 Pfizer-vaccinated employees of the university infected with different strains of the virus—Alpha, Beta, Gamma, and Delta.

The study found that antibodies measured after breakthrough cases were more abundant and more effective than antibodies generated two weeks after a second dose of the Pfizer vaccine. “You can’t get a better immune response than this,” said Fikadu Tafesse, the author of the report and an assistant professor at the OHSU School of Medicine.

“We have not examined the Omicron variant specifically," Tafesse added, "but based on the results of this study we would anticipate that breakthrough infections from the Omicron variant will generate a similarly strong immune response among vaccinated people."

Greater immunity, given the vast number of people contracting COVID-19 during the current surge, may mean the pandemic may soon ease up. “The incredible number of infections is building up population-level immunity. That’ll be crucial in terms of muting future waves,” Joshua Michaud, associate director for global health policy at the Kaiser Family Foundation, told Vox.

That being said, the Omicron variant is proving adept at evading prior infections from different variants. Preprint studies from South Africa found the risk of reinfection with Omicron during South Africa’s fourth wave was substantially higher than the risk seen during the country’s second and third waves, which were dominated by Beta and Delta, respectively. Another study from the Imperial College of London found risk of reinfection with the Omicron variant was 5.4 times greater than that of the Delta variant.

財(cái)富中文網(wǎng)所刊載內(nèi)容之知識(shí)產(chǎn)權(quán)為財(cái)富媒體知識(shí)產(chǎn)權(quán)有限公司及/或相關(guān)權(quán)利人專屬所有或持有。未經(jīng)許可,禁止進(jìn)行轉(zhuǎn)載、摘編、復(fù)制及建立鏡像等任何使用。
0條Plus
精彩評(píng)論
評(píng)論

撰寫或查看更多評(píng)論

請(qǐng)打開財(cái)富Plus APP

前往打開

            主站蜘蛛池模板: 沧源| 礼泉县| 本溪| 临清市| 会同县| 招远市| 六盘水市| 普格县| 兴安县| 循化| 广河县| 城市| 富蕴县| 瑞安市| 宽城| 兴山县| 台山市| 黎川县| 蚌埠市| 于都县| 扶余县| 读书| 信阳市| 武乡县| 贺州市| 云梦县| 潼南县| 珲春市| 环江| 井冈山市| 南部县| 金秀| 双城市| 聊城市| 博兴县| 建昌县| 明光市| 开封县| 沭阳县| 平乐县| 东光县|